Knockdown of vps54 aggravates tamoxifen-induced cytotoxicity in fission yeast

Abstract

Tamoxifen (TAM) is an anticancer drug used to treat estrogen receptor (ER)‒positive breast cancer. However, its ER-independent cytotoxic and antifungal activities have prompted debates on its mechanism of action. To achieve a better understanding of the ER-independent antifungal action mechanisms of TAM, we systematically identified TAM-sensitive genes through microarray screening of the heterozygous gene deletion library in fission yeast (Schizosaccharomyces pombe). Secondary confirmation was followed by a spotting assay, finally yielding 13 TAM-sensitive genes under the drug-induced haploinsufficient condition. For these 13 TAM-sensitive genes, we conducted a comparative analysis of their Gene Ontology (GO) ‘biological process’ terms identified from other genome-wide screenings of the budding yeast deletion library and the MCF7breast cancer cell line. Several TAM-sensitive genes overlapped between the yeast strains and MCF7 in GO terms including ‘cell cycle’ (cdc2, rik1, pas1, and leo1), ‘signaling’ (sck2, oga1, and cki3), and ‘vesicle-mediated transport’ (SPCC126.08c, vps54, sec72, and tvp15), suggesting their roles in the ER-independent cytotoxic effects of TAM. We recently reported that the cki3 gene with the ‘signaling’ GO term was related to the ER-independent antifungal action mechanisms of TAM in yeast. In this study, we report that haploinsufficiency of the essential vps54 gene, which encodes the GARP complex subunit, significantly aggravated TAM sensitivity and led to an enlarged vesicle structure in comparison with the SP286 control strain. These results strongly suggest that the vesicle-mediated transport process might be another action mechanism of the ER-independent antifungal or cytotoxic effects of TAM.

Multifaceted role of RNA editing in promoting loss-of-function of PODXL in cancer

“…(Borg et al, 2016;Kusumoto et al, 2017;Lee et al, 2017;Taniuchi et al, 2018;Zhang et al, 2019;He et al, 2020). In addition, PODXL plays important role in cancer metastasis by promoting cell migration (Lin et al, 2014;Kusumoto et al, 2017;Lee et al, 2017Lee et al, , 2021, cell invasion (Wu et al, 2013;Lin et al, 2014;Chan et al, 2016;Kusumoto et al, 2017), cell extravasation (Fro ¨se et al, 2018), immune evasion (Amo et al, 2015), and chemoresistance (Huang et al, 2015;Zhou et al, 2015;Lee et al, 2017;Tamayo-Orbegozo et al, 2020). Therefore, PODXL is also a valuable therapeutic target for cancer metastasis (Snyder et al, 2015;Chijiiwa et al, 2016).…”